AstraZeneca’s Danicopan Among Four Orphans Up For EU Approval Decision

The European Medicines Agency is due to decide whether to back pan-EU marketing authorization for 11 new products, including four orphan drugs.

Thumb up and thumb down
It's decision time for 11 products at the EMA • Source: Shutterstock

AstraZeneca/Alexion’s danicopan, Biogen’s tofersen, Incyte’s retifanlimab and Vifor/Travere Therapeutics’ sparsentan are four orphan drug candidates that could potentially be backed for pan-EU marketing approval this week. 

The four drugs are among 11 new products listed as being up for an opinion on whether they should be...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography